Literature DB >> 29183158

Critical Roles of Glutaredoxin in Brain Cells-Implications for Parkinson's Disease.

Olga Gorelenkova Miller1, John J Mieyal1.   

Abstract

SIGNIFICANCE: Glutaredoxin (Grx)1, an evolutionarily conserved and ubiquitous enzyme, regulates redox signal transduction and protein redox homeostasis by catalyzing reversible S-glutathionylation. Grx1 plays different roles in different cell types. In Parkinson's disease (PD), Grx1 regulates apoptosis signaling in dopaminergic neurons, so that loss of Grx1 leads to increased cell death; in microglial cells, Grx1 regulates proinflammatory signaling, so that upregulation of Grx1 promotes cytokine production. Here we examine the regulatory roles of Grx1 in PD with a view toward therapeutic innovation. Recent Advances: In postmortem midbrain PD samples, Grx1 was decreased relative to controls, specifically within dopaminergic neurons. In Caenorhabditis elegans models of PD, loss of the Grx1 homologue led to exacerbation of the neurodegenerative phenotype. This effect was partially relieved by overexpression of neuroprotective DJ-1, consistent with regulation of DJ-1 content by Grx1. Increased GLRX copy number in PD patients was associated with earlier PD onset; and Grx1 levels correlated with levels of proinflammatory tumor necrosis factor-α in mouse and human brain samples. In vitro studies showed Grx1 to be upregulated on proinflammatory activation of microglia. Direct overexpression of Grx1 increased microglial activation; silencing Grx1 diminished activation. Grx1 upregulation in microglia corresponded to increased neuronal cell death in coculture. Overall, these studies identify competing roles of Grx1 in PD etiology. CRITICAL ISSUES: The dilemma regarding Grx1 as a PD therapeutic target is whether to stimulate its upregulation for neuroprotection or inhibit its proinflammatory activity. FUTURE DIRECTIONS: Further investigation is needed to understand the preponderant role of Grx1 regarding dopaminergic neuronal survival.

Entities:  

Keywords:  Parkinson's disease; glutaredoxin; neuroinflammation; neuroprotection

Mesh:

Substances:

Year:  2018        PMID: 29183158      PMCID: PMC6391617          DOI: 10.1089/ars.2017.7411

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  133 in total

1.  Protein oxidation in the brain in Alzheimer's disease.

Authors:  M Y Aksenov; M V Aksenova; D A Butterfield; J W Geddes; W R Markesbery
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 2.  The heterogeneity of idiopathic Parkinson's disease.

Authors:  Thomas Foltynie; Carol Brayne; Roger A Barker
Journal:  J Neurol       Date:  2002-02       Impact factor: 4.849

3.  Oxidative stress inhibits vascular K(ATP) channels by S-glutathionylation.

Authors:  Yang Yang; Weiwei Shi; Ningren Cui; Zhongying Wu; Chun Jiang
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

4.  Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson's disease.

Authors:  Elizabeth A Sabens; Anne M Distler; John J Mieyal
Journal:  Biochemistry       Date:  2010-03-30       Impact factor: 3.162

Review 5.  Aspects of the biological redox chemistry of cysteine: from simple redox responses to sophisticated signalling pathways.

Authors:  Claus Jacob; Iona Knight; Paul G Winyard
Journal:  Biol Chem       Date:  2006 Oct-Nov       Impact factor: 3.915

6.  DJ-1 loss by glutaredoxin but not glutathione depletion triggers Daxx translocation and cell death.

Authors:  Uzma Saeed; Ajit Ray; Rupanagudi Khader Valli; A Madan Ram Kumar; Vijayalakshmi Ravindranath
Journal:  Antioxid Redox Signal       Date:  2010-07-15       Impact factor: 8.401

Review 7.  Parkinson disease subtypes.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

Review 8.  Glutathione--a review on its role and significance in Parkinson's disease.

Authors:  Heather L Martin; Peter Teismann
Journal:  FASEB J       Date:  2009-06-19       Impact factor: 5.191

9.  Mitochondrial neuronal uncoupling proteins: a target for potential disease-modification in Parkinson's disease.

Authors:  Philip Wl Ho; Jessica Wm Ho; Hui-Fang Liu; Danny Hf So; Zero Hm Tse; Koon-Ho Chan; David B Ramsden; Shu-Leong Ho
Journal:  Transl Neurodegener       Date:  2012-01-13       Impact factor: 8.014

Review 10.  Dysregulation of glutathione homeostasis in neurodegenerative diseases.

Authors:  William M Johnson; Amy L Wilson-Delfosse; John J Mieyal
Journal:  Nutrients       Date:  2012-10-09       Impact factor: 5.717

View more
  5 in total

Review 1.  Redox Regulation via Glutaredoxin-1 and Protein S-Glutathionylation.

Authors:  Reiko Matsui; Beatriz Ferran; Albin Oh; Dominique Croteau; Di Shao; Jingyan Han; David Richard Pimentel; Markus Michael Bachschmid
Journal:  Antioxid Redox Signal       Date:  2020-01-23       Impact factor: 8.401

2.  Glutaredoxin 1 up-regulates deglutathionylation of α4 integrin and thereby restricts neutrophil mobilization from bone marrow.

Authors:  Yuanyuan You; Junli Chen; Feimei Zhu; Qian Xu; Lu Han; Xiang Gao; Xiaoyu Zhang; Hongbo R Luo; Junming Miao; Xiaodong Sun; Hongyu Ren; Yu Du; Lijuan Guo; Xiaoying Wang; Yi Wang; Shanze Chen; Ning Huang; Jingyu Li
Journal:  J Biol Chem       Date:  2018-12-31       Impact factor: 5.157

Review 3.  Oxidative Stress Orchestrates MAPK and Nitric-Oxide Synthase Signal.

Authors:  Tsuyoshi Takata; Shoma Araki; Yukihiro Tsuchiya; Yasuo Watanabe
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

4.  Mechanism of miR-132-3p Promoting Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson's Disease.

Authors:  Xin Gong; Mengyi Huang; Lei Chen
Journal:  eNeuro       Date:  2022-01-25

5.  Metabolic Profile and Pathological Alterations in the Muscle of Patients with Early-Stage Amyotrophic Lateral Sclerosis.

Authors:  Débora Lanznaster; Clément Bruno; Jérôme Bourgeais; Patrick Emond; Ilyess Zemmoura; Antoine Lefèvre; Pascal Reynier; Sébastien Eymieux; Emmanuelle Blanchard; Patrick Vourc'h; Christian R Andres; Salah Eddine Bakkouche; Olivier Herault; Luc Favard; Philippe Corcia; Hélène Blasco
Journal:  Biomedicines       Date:  2022-06-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.